user TORONTO, Feb. 24, 2022 — Arch Biopartners Inc. (“Arch Biopartners”, “Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for treating organ damage caused by inflammation, announced today that it has been named to the 2022 TMX Venture 50 List of Top Performing TSX Venture Exchange … Read more
LSALT Peptide (LSALT) is a novel drug candidate that targets acute organ inflammation in the lungs, liver and kidneys common in several indications, including moderate to severe cases of COVID-19, regardless of variant type. TORONTO, Feb. 14, 2022 (GLOBE NEWSWIRE) — Arch Biopartners Inc. (“Arch Biopartners”, “Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: … Read more
TORONTO, Feb. 08, 2022 (GLOBE NEWSWIRE) — Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that the Company has arranged a shares for debt transaction to settle an aggregate of $424,767.07 in interest accrued up to December 31, 2021 on all five of the deferred convertible notes outstanding … Read more
Published in the AAAS journal Science Advances this paper by key members of the Arch Biopartners scientific team led by Dr. Daniel Muruve at the University of Calgary, and their collaborators, demonstrated the mechanism by which DPEP-1 regulates the recruitment of leukocytes (i.e. inflammation) to the kidney following ischemia reperfusion injury, which is injury that … Read more
TORONTO, Feb. 03, 2022 (GLOBE NEWSWIRE) — Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that a scientific team led by Dr. Daniel Muruve at the University of Calgary, and their collaborators, have published a paper in the journal Science Advances describing the mechanism of action for dipeptidase-1 … Read more
LSALT Peptide (LSALT) is a novel drug candidate that targets acute organ inflammation in the lungs, liver and kidneys common in several indications, including moderate to severe cases of COVID-19, regardless of variant type. TORONTO, Jan. 04, 2022 (GLOBE NEWSWIRE) — Arch Biopartners Inc. (“Arch Biopartners”, “Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: … Read more
Authors Amanda Barry, Warunya Panmanee, Daniel J. Hassett Details Published in Infection and Immunity, Volume 89, Number 11 – 15 October 2021Read the full publication at ASM Journals or download the PDF Abstract Cutaneous thermal injuries from burns/explosives are a major cause of morbidity and mortality and represent a monumental burden on our current health … Read more
LSALT Peptide (LSALT) is a novel drug candidate that targets acute organ inflammation in the lungs, liver and kidneys which is common in moderate to severe cases of COVID-19, regardless of variant type. LSALT is the first novel therapeutic to join the Canadian Treatments for COVID-19 trial, a multi-centre adaptive, randomized, open-label, controlled clinical trial … Read more
Le peptide LSALT (LSALT) est un nouveau candidat médicament en cours de développement pour cibler l’inflammation aiguë des organes dans les poumons, le foie et les reins qui est courante dans les cas modérés à graves de COVID-19, quelles que soient les variantes du virus. LSALT est le premier nouveau médicament à rejoindre l’essai Canadian … Read more
TORONTO, Oct. 15, 2021 (GLOBE NEWSWIRE) — At the request of the Investment Industry Regulatory Organization of Canada (IIROC), Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) wishes to confirm that the Company’s management is unaware of any undisclosed material change in the Company’s operations that would account for the … Read more